Kimberly Browne
Adult Health · Ste Genevieve, MONPI 1710239496
Payments from drug & device makers
Across 71 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$237
- Lilly USA, LLC$201
- Novo Nordisk$153
- Merck$88
- Urovant Sciences Inc$64
- Novartis$56
- plus $543 from 19 others
What the payments were for
- Food & beverage$1,16687%
- Education$17513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $237 |
| Lilly USA, LLC | 11 | $201 |
| Novo Nordisk | 9 | $153 |
| Merck | 6 | $88 |
| Urovant Sciences Inc | 5 | $64 |
| Novartis | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| AbbVie | 3 | $48 |
| Amgen | 3 | $47 |
| Abbott | 2 | $46 |
| Boston Scientific | 1 | $35 |
| Philips North America LLC | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| AstraZeneca | 2 | $32 |
| Grifols USA, LLC | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| Pfizer | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Exact Sciences | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,341 in reported general payments places this provider in the 65th percentile of 555 adult health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 190 | $98,566 |
| GemtesaVibegron | 67 | $54,154 |
| Methenamine Hippurate | 213 | $11,906 |
| Tamsulosin Hcl | 552 | $6,056 |
| Estradiol | 72 | $4,893 |
| Finasteride | 453 | $4,180 |
| Trospium Chloride ErTrospium Chloride | 13 | $4,154 |
| Dutasteride | 161 | $3,518 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 13 | $2,567 |
| Oxybutynin Chloride ErOxybutynin Chloride | 159 | $2,564 |
| Trospium Chloride | 22 | $2,042 |
| Solifenacin Succinate | 49 | $1,903 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 80 | $1,715 |
| Bethanechol Chloride | 33 | $1,411 |
| Cephalexin | 95 | $1,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $237 | $98,566190 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $52 | $54,15467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 555 adult health providers in Missouri.
Other adult health in Ste Genevieve
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Katie MurrayIndependence$59K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.